*Chloroquine (CQ): a drug of choice for malaria treatment* - Malaria is an infectious disease that has been present in the tropics for much of history. It varies widely in epidemiology and clinical manifestation and is responsible for an estimated 216 million clinical episodes and approximately 655,000 deaths per year, of which approximately 90% occur in Africa (WHO 2011). The variability in the spectrum of malarial diseases is the result of several factors, including the distribution of the two primary species of malaria parasites ( *Plasmodium falciparum* and *Plasmodium vivax* ), their levels of susceptibility to antimalarial drugs, the distribution and efficiency of mosquito vectors, climate and other environmental conditions and the behaviour and level of acquired immunity of the exposed human populations (Bloland 2001). Due to the lack of an effective vaccine, malaria is currently incurable and thus its case management depends solely on anti-malarials (WHO 1973, 1984). In the Western world, the first anti-malarial used to treat human malaria was quinine, which is extracted from the bark of the cinchona tree and was described as early as 1632 (Baird et al. 1996). In Chinese medicine, the use of *Artemisia annua* (qinghao) plants for the treatment of intermittent fever/malaria was described as early as 283-343 AD. Around 340 AD, in Hong Ge's *Handbook of Prescriptions for Emergency Treatment* , a cold extraction method of qinghao was described for the treatment of intermittent fevers (Klayman 1985). Although primaquine and quinacrine were produced after World War I (1914-1918) and remained effective for malaria treatment for a period of time, the intense demand for other anti-malarials led to the discovery of CQ by Bayer in Germany (Thompson & Werbel 1972).

CQ, a 4-aminoquinoline derivative of quinine, was first synthesised in 1934 ( [@B154] ) and has since become the most widely used antimalarial drug. Historically, CQ was used to combat malaria in 1946 after the Second World War. Since then, it has been considered to be the drug of choice for the treatment of non-severe, un-complicated malaria and for chemoprophylaxis. Apart from certain toxic side effects, such as retinal and psychiatric symptoms, cardiac disorders, respiratory depression, neurological problems and severe gastro-intestinal irritation ( [@B153] ), certain unique properties, including high efficacy, wide distribution, ready availability, quick metabolism, inexpensiveness and high therapeutic index ( [@B112] ), made CQ the drug of choice for treating malaria ( [@B24] ). Over the years, CQ has proven to be one of the most successful and important drugs ever deployed against malaria, especially in the highly endemic areas of Africa, where the malaria parasite *P. falciparum* infects nearly every child ( [@B168] ). This efficiency of CQ also prompted the World Health Organization (WHO) to spearhead projects and establish large mass drug administration programs using CQ ( [@B83] , [@B174] ). The introduction of CQ near the end of Second World War brought dramatic new power to malaria control programs ( [@B167] ) and these efforts further reduced the incidence of malaria in most of the endemic regions in the world. However, the malaria eradication campaign started by the WHO in the 1950s excluded Africa, the continent with the highest burden of malaria and focused on the rest of the world. As such, by the late 1950s and early 1960s, malaria was eradicated in most of the Western world and was reduced to its historically lowest level in Asia and the Americas, but remained at approximately the same level in Africa ( [@B148] ).

*Mechanism of action of CQ* - CQ acts on the endolysosomal system of malaria parasites, causing morphologic changes and haemoglobin accumulation in endocytic vesicles ( [@B48] , [@B44] ). Being alkaline in nature, CQ accumulates in high concentrations within the digestive vacuole (DV) of the parasite and raises its pH. Because the DV is acidic in pH, the deprotonation of CQ renders the DV alkaline ( [@B110] , [@B110] ). CQ then induces the rapid clumping of the malarial pigment and eventually inhibits the parasitic enzyme haeme polymerase, which normally converts the toxic ferric haeme (ferriprotoporphyrin IX) into the non-toxic haemozoin (5-haematin). This inhibition results in the accumulation of toxic ferric haeme, leading to lysis and, ultimately, parasite death ( [@B127] , [@B44] ). Studies have suggested that the mechanism of action of CQ relies heavily on the accumulation of high concentrations of the drug ( [@B48] , [@B44] ).

*CQ resistance (CQR) is a major hurdle to malaria control* - The tremendous success of CQ and its heavy use for almost 12 years ( [@B176] ) led to the development of resistance in *P. falciparum* during the late 1950s ( [@B86] , [@B100] , [@B179] , [@B125] , [@B113] ). The contribution of the extensive use and misuse of CQ to the selection of resistant parasites became particularly evident during the Global Malaria Eradication Campaign, which was launched by the WHO in 1955. CQR was implicated in the spread of malaria to new areas and the re-emergence of malaria in areas where the disease was previously eradicated due to population movement ( [@B17] , [@B152] ). CQR was reported for the first time at the Thailand-Cambodia border in 1957 and the Venezuela-Colombia border in 1959 and eventually spread to other countries throughout the world ( [@B169] , [@B91] , [@B126] ). Moreover, several recent molecular epidemiological studies have identified at least six independent origins of CQR from different regions of the world ( [@B92] , [@B167] ). Despite the suggested multiple independent origins of CQR, CQR parasites share some common phenotypes, such as increased 50% inhibitory concentration (IC ~50~ ), chemosensitisation, reduced CQ accumulation, low pH in the DV and similar genetic mutations ( [Jiang et al. 2006](#B70) ). Drug pressure in the field is also considered to be an essential prerequisite for the development of resistance ( [@B166] , [@B116] ). However, the rate at which drug resistance spreads and how the resistant mutants survive in nature are still a matter of investigation ( [@B148] , [@B6] , [@B69] ). Several models, including the degree of drug use, drug elimination half-life, host heterogeneity ( [@B62] ), parasite biomass ( [@B60] ), parasite fitness ( [@B163] ), malaria transmission intensity ( [@B61] ), host immunity and intrahost dynamics ( [@B59] ), were developed to better understand this drug resistance ( [@B149] , [@B148] , [@B150] ). Because CQR parasites have been experimentally shown to have greater fitness potential in CQ environments than CQS parasites ( [@B163] ), the resistant parasites were able to spread and establish themselves throughout the *P. falciparum* malaria-endemic zones. Following the emergence and spread of CQR, the drug policies of many countries were revised and several new drugs were introduced in the field either as single agents or in combination therapies. Gradually, *P. falciparum* developed resistance to nearly all anti-malarials in use ( [Table I](#t01){ref-type="table"} ), although the geographical distribution of resistance to any single-agent antimalarial drug varies greatly ( [@B17] , [@B96] ). Like CQ, the extensive deployment of other antimalarial drugs also placed tremendous selection pressure on *P. falciparum* to evolve mechanisms of resistance ( [@B5] ). Additionally, cross-resistance and the genetic plasticity of the parasite contributed to CQR ( [@B171] ). Despite the prevalence of CQR in *P. falciparum* , CQ still remains the drug of choice for the treatment of non-severe *P. falciparum* and non- *P. falciparum* infections in many malaria-endemic countries and its several unique properties make it advantageous over all other anti-malarial drugs. Despite the introduction of several therapies to treat complicated and non-complicated malaria, CQ still has a prominent place in malaria treatment. Thus, the development of CQR poses a great hurdle to malaria control measures and has contributed to rollbacks in malaria programmes ( [@B148] ).
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*Genetics of CQR in P. falciparum - Identification of the Pfcrt gene* - Soon after CQR *P. falciparum* isolates were found to be widespread in malaria-endemic zones, the mutagenic basis of CQR was made evident by several clinical and epidemiological studies ( [@B165] , [@B47] ). Phenotypic studies involving genetic crosses between CQR and CQ-sensitive (CQS) strains further supported the hypothesis of the genetic basis of CQR ( [@B165] ) and genetic *loci* on chromosome 13 ( *Pfnhe* 1 gene) ( [Fig. 1](#f01){ref-type="fig"} ) and chromosome 5 ( *Pfmdr* 1 gene) ( [Fig. 1](#f01){ref-type="fig"} ) were proposed to be associated with higher IC ~50~ values in the progeny of genetic crosses ( [@B165] , [@B46] ). However, a direct association between *Pfnhe* 1 gene mutations and CQR could not be established. Instead, *Pfnhe1* mutations were found to correlate well with quinine in several studies ( [@B26] , [@B65] , [@B66] ). Mutations in *Pfmdr1* , which encodes a homolog of the human multidrug resistance *p* -glycoprotein ( *PfPgh* 1), were also found to be associated with CQR ( [@B34] , [@B102] , [@B36] , [@B140] , [@B155] ), but the contribution of *Pfmdr1* in modulating CQR remains debatable ( [@B65] , [@B66] ). It was later established that CQR is inherited as a single *locus* in a genetic cross between the CQR Dd2 (Indochina) and CQS HB3 (Honduras) clones and this *locus* was identified to be the single determinant of CQ sensitivity ( [@B165] , [@B144] , [@B47] ). The CQR phenotype was further mapped to a 48-Kb chromosomal *locus* harbouring the highly interrupted gene *Pfcrt* ( *P. falciparum* CQR transporter) ( [Figs 1](#f01){ref-type="fig"} , [2](#f02){ref-type="fig"} ). This gene is present on chromosome 7, spans 3.1 kb and has 13 exons ranging in size from 45-269 bp. It produces a 1,275-bp cDNA that encodes the 424-amino acid 48.6-kDa *Pf* CRT protein, which has 10 transmembrane domains (TMDs) ( [@B165] , [@B144] , [@B47] , [@B19] ). Further evidence establishing *Pfcrt* as a CQR determinant came from studies of culture-adapted field isolates, which showed that CQR *P. falciparum* isolates had extensive linkage disequilibrium (LD) surrounding a 36-Kb segment of *Pfcrt* ( [@B177] ).

Fig. 1schematic representation of the three genes, *Pfnhe* 1, *Pfmdr* 1 and *Pfcrt* , respectively, associated with chloroquine resistance in *Plasmodium falciparum* . The red boxes depict exons.

Fig. 2: location of the \~100 Kb segment present in the seventh chromosome of *Plasmodium falciparum* harbouring the transporter genes, *Pfcrt* and *var* gene. Further \~36 Kb segment is highlighted encompassing the eight transporter genes including the *Pfcrt* gene and a more schematic view of the *Pfcrt* gene with its 13 exons and the K76T mutation is highlighted. The five amino acids present from 72-76 position in exon 2 characterise the resistant (CVIET and SVMNT) and sensitive (CVMNK) chloroquine resistance *Pfcrt* haplotypes.

*Putative functional role of PfCRT in P. falciparum* - The endogenous function of *Pf* CRT remains unknown, but its transmembrane structure and cellular location suggest that it is involved in the transport of critical metabolites, such as drugs and maintains the pH balance in the DV of *P. falciparum* ( [@B42] , [@B15] , [@B44] ). Other potential roles for *Pf* CRT include the expulsion of amino acids resulting from haemoglobin digestion from the DV and indirect involvement in maintaining H ^+^ balance in the DV ( [@B71] ). The roles of other transporters, such as *Pf* VP2, the Ca ^+2^ /H ^+^ antiporter VCX1, PFE0785c and ATPase/synthase (PF11_0412 and PFC0840w), which might also play crucial roles in CQR, have also been well documented ( [@B71] ). Moreover, phylogenetic analyses predict *Pf* CRT to be a member of the drug/metabolite transporter superfamily of electrochemical potential driven transporters, thus supporting its hypothesised roles in *P. falciparum* ( [@B88] ).

*PfCRT, glutathione (GSH) and the human immune response* - Human immune responses play an important role in shaping the ability of the host to resolve drug-resistant infections harbouring mutant *Pfcrt* ( [@B35] ), as failures in treatment are generally associated with specific polymorphisms in the parasite genome or gene copy number ( [@B114] ). A low level of CQR *P. falciparum* and acquired protective immunity can explain why CQ treatment is able to successfully cure some infections harbouring mutant *Pfcrt* parasites in semi-immune individuals ( [@B168] , [@B35] ) and why, at other times, the immune response allows a relatively ineffective drug to clear an infection without any therapy ( [@B135] , [@B56] ). Altered intracellular levels of GSH have been shown to cause a corresponding shift in CQ susceptibility in *P. falciparum* ( [@B54] ). Additional indirect evidence has suggested a potential link between CQR and GSH ( [@B55] ), which originated from the observation that the *Pfmrp* gene, which is localised to the parasite surface, is disrupted in CQR ( [@B119] ). Moreover, a recent report found that *Pf* CRT homologs in *Arabidopsis thaliana* mediate GSH transport and stress tolerance when assayed in *Xenopus* oocysts ( [@B89] ).

*The K76T mutation in PfCRT: a key factor?* - Sequence comparisons of *Pf* CRT in CQR and CQS *P. falciparum* have identified several mutations, among which the mutation of residue 76 (wild type K to the mutant T) could be directly associated with CQR. This finding was confirmed by allelic exchange studies ( [@B47] , [@B141] , [@B80] ). Other additional single nucleotide polymorphisms (SNPs) present in exons 2, 3, 4, 6, 9, 10 and 11 of the *Pfcrt* gene have also been proposed to have some association with CQR. Similarly, at the protein level, approximately 32 mutations in the 10 α-helical TMD of *Pf* CRT have been reported to be associated with CQR. Studies have suggested that these mutations might epistatically interact with the K76T mutation and might also evolve to maintain homeostasis ( [@B47] , [@B177] ). However, these mutations have been casually associated with resistance in vitro and in vivo and even with altered drug accumulation ( [@B134] , [@B133] , [@B132] ). Regardless of the exact knowledge of these mutations, in general, it was found that parasites that are resistant to CQ and that bear mutations in *Pf* CRT accumulate less CQ due to either active energy-dependent CQ efflux ( [@B78] , [@B134] ) or the passive efflux of diprotic CQ ( [@B113] ).

*Compensatory mutations within Pfcrt and Pfmdr1* - Recent studies have suggested that *Pf* CRT mutations may affect parasite survival by switching back to their CQS form in the absence of drug pressure, perhaps owing to the low fitness properties of the resistant *Pf* CRT in competing against the sensitive *Pf* CRT, as observed in Malawi, Kenya and Hainan ( [@B79] , [@B94] , [@B95] , [@B164] , [@B81] , [@B105] ). On the contrary, some parasite lines ( *e.g* ., FCB and Dd2) grow well in vitro, even in the absence of drug pressure, suggesting the presence of potential compensatory mutations within *Pf* CRT. These compensatory changes within *Pf* CRT may not fully restore the biological functions of the protein and further changes in other parts of the genome may be required ( [@B71] ). This compensatory role is believed to be played by the *Pfmdr1* gene. This hypothesis is supported by the fact that strong LD was found between variants of both the *Pfcrt* and *Pfmdr1* genes ( [@B38] , [@B1] , [@B36] , [@B101] , [@B146] ). Furthermore, *Pfmdr1* was observed to be non-randomly associated with the mutant *Pfcrt* gene and directly related to CQR to improve parasite fitness ( [@B45] ). Both genes also combine in a region-specific manner to create higher levels of drug resistance ( [@B129] ). However, the precise role of the *Pfmdr1* gene in the efflux mechanism of CQ in *P. falciparum* is still unclear ( [@B76] , [@B77] ). It has been proposed that copy number variations influence *Pfmdr1* expression in response to CQ and mefloquine selection or mutations in *Pfcrt* , suggesting a direct association between these two genes ( [@B29] , [@B118] , [@B6] , [@B36] , [@B66] ). Moreover, a low copy number *Pfmdr1* in *P. falciparum* also increases its susceptibility to other drugs ( [@B140] ). Thus, it seems that *Pfcrt* has a causal effect on CQR, while *Pfmdr1* acts as a secondary modulator ( [@B11] , [@B107] , [@B67] , [@B70] ). Surprisingly, apart from *Pfmdr1* , no other gene has been found to be associated with CQR, although quantitative CQ responses differ in CQR and CQS strains, even when the *Pfcrt* and *Pfmdr1* genes remain unchanged. This finding indicates that the level of the CQ response may be influenced by additional genes ( [@B49] , [@B123] , [@B102] ). Moreover, studies on culture-adapted isolates that harbour the mutant *Pfcrt* gene reported low CQ IC ~50~ values that failed to meet the standard criteria for CQR, providing indubitable evidence that mutant *Pfcrt* is insufficient to confer CQR to all genetic backgrounds, even though the strains showed high CQ tolerance and recrudescence under CQ pressure ( [@B156] ).

*Pfcrt mutations and haplotypes: global distribution of different haplotypes* - Amino acid polymorphisms have been found in exon 2 of the *Pfcrt* gene at residues 72, 74, 75 and 76 in *P. falciparum* isolates, suggesting that they may be involved in the genetic characterisation of CQR and CQS ( [Fig. 2](#f02){ref-type="fig"} ). Accordingly, whereas the C ~72~ V ~73~ M ~74~ N ~75~ K ~76~ haplotype is considered to be CQS, parasites with polymorphisms at any of these amino acid positions are considered to be CQR ( [@B9] , [@B10] ) ( [Fig. 2](#f02){ref-type="fig"} ). For CQR *P. falciparum* , two principal haplotypes, with the amino acid sequences C ~72~ V ~73~ I ~74~ E ~75~ T ~76~ and S ~72~ V ~73~ M ~74~ N ~75~ T ~76~ ( [@B9] , [@B10] ) ( [Fig. 2](#f02){ref-type="fig"} ), are widely distributed. Based on nucleotide sequence data, the SVMNT haplotype is further categorised as either S ~agt~ VMNT or S ~tct~ VMNT, a di-nucleotide polymorphism at codon 72, in which the sequence is changed from AGT to TCT. However, this nucleotide change does not lead to an amino acid substitution, as both AGT and TCT code for serine ( [@B92] ). Due to the widespread yet structured present-day distribution across *P. falciparum* -endemic zones across the globe, these two haplotypes are hypothetically considered to be CQR mother haplotypes and the 19 minor haplotypes are believed to have been derived from them ( [@B9] , [@B10] ) ( [Table II](#t02){ref-type="table"} ). While it has been established that CVIET and SVMNT are widely prevalent, whether all of the other minor haplotypes were derived from these two or evolved independently is still an open question. It appears that these multiple resistant haplotypes may have evolved independently, but that only some of them have been able to selectively sweep through populations. In addition to the accepted five foci of origin for CQR *P. falciparum* , specifically, CVIET (Southeast Asia and Africa), S ~agt~ VMNT (Asia, South America and Tanzania), S ~tct~ VMNT (South America and Angola), CVMET (Colombia) and CVMNT (South America and the Philippines), a sixth *focus* has been described in India and Iran ( [@B92] , [@B180] , [@B167] ). An in-depth description of the distribution of the different haplotypes in the three malaria-endemic continents (Asia, Africa and South America) is discussed below.

TABLE IIVarious derived (minor) chloroquine resistance (CQR) *Pfcrt* haplotypes with their reported countries and relevant referencesDerived/minor haplotypesReported countries of CQRReferencesCVIDTCambodia, India, Angola, Madagascar, Indochinese Peninsula, Vietnam, China, PhilippinesLim et al. (2003), Huaman et al. (2004), Cooper et al. (2005), Randrianarivelojosia et al. (2006), Keen et al. (2007), Rason et al. (2007), Yang et al. (2007), Niang et al. (2008), Gama et al. (2010), Takahashi et al. (2012)CVIKTIndonesia, Papua New GuineaMehlotra et al. (2001, 2008), Nagesha et al. (2003), Huaman et al. (2004), Cooper et al. (2005)SVIETIndonesian Papua New Guinea, Congo, Central Africa RepublicNagesha et al. (2003), Plummer et al. (2004), Menard et al. (2006), Niang et al. (2008)SVIEKCentral Africa RepublicMenard et al. (2006)CVIEKCentral Africa Republic, SudanMenard et al. (2006), Summers et al. (2012)CVMNTPNG, Cambodia, India, Brazil, Peru, Ecuador, Columbia, Philippines, Angola, Iran, IndiaCortese et al. (2002), Lim et al. (2003), Nagesha et al. (2003), Vieira et al. (2004), Mittra et al. (2006), Echeverry et al. (2007), Keen et al. (2007), Pati et al. (2007), Restrepo et al. (2008), Zakeri et al. (2008), Gama et al. (2010), Mixon-Hayden et al. (2010), Takahashi et al. (2012)SVMITGuyanaPlummer et al. (2004), Cooper et al. (2005), Menard et al. (2006), Takahashi et al. (2012)SVMETColumbia, Central Africa RepublicPlummer et al. (2004), Menard et al. (2006)SVMDTPhilippinesHatabu et al. (2009), Takahashi et al. (2012)RVMNTGuyanaPlummer et al. (2004), Cooper et al. (2005)CVMETColumbiaEcheverry et al. (2007), Yang et al. (2007)CVMNNIndonesiaHuaman et al. (2004), Cooper et al. (2005)CVTNTCambodiaLim et al. (2003), Durand et al. (2004)CVINTCentral Africa Republic, AngolaMenard et al. (2006), Gama et al. (2010)CVMHTPhilippinesYang et al. (2007)CVMDTAngola, PhilippinesHatabu et al. (2009), Gama et al. (2010), Takahashi et al. (2012)CVIEAThailand (cloneJ9)Chaijaroenkul et al. (2011), Summers et al. (2012)CVIEILaboratory strain (106/1-I)Cooper et al. (2002), Summers et al. (2012)CVIENLaboratory strain (106/1-N)Cooper et al. (2002), Summers et al. (2012)

*Distribution of the CQR-Pfcrt haplotypes in Asia* - The distribution of the CQR- *Pfcrt* haplotypes presents a unique pattern in Asia, particularly in Southeast Asia \[Cambodia, Thailand, Bangladesh, Laos, Indochina, Indonesia, Philippines, Papua New Guinea (PNG), East Timor Islands, Solomon Islands and Vanuatu\] and South Asia (India, Pakistan, Sri Lanka and Iran). The CVIET mother haplotype is proposed to have originated at the Thailand-Cambodia border in Southeast Asia ( [@B91] , [@B117] ). In Thailand and Bangladesh, the CVIET haplotype is the major reported haplotype ( [@B64] , [@B147] ) and, very recently, a new haplotype, CVIEA, was also observed in Thailand ( [@B20] ). In Cambodia, apart from CVIET, three more derived haplotypes (CVIDT, CVTNT and CVMNT) have also been reported ( [@B82] ). In Laos, CVIET and SVMNT haplotypes have been reported, with the latter having a relatively higher frequency ( [@B32] ). Interestingly, the Philippine Islands were found to be dominated by SVMNT and its derived haplotypes (CVMNT and CVMHT) ( [@B22] , [@B178] ), with a recent report indicating the distribution of the CVIET-derived haplotype CVIDT ( [@B68] ). The *Pfcrt* haplotypic view of PNG is quite unusual; despite its geographic proximity to the Southeast Asian focus of the resistance-carrying CVIET haplotype, the CQR parasites in this country harbour haplotypes that are similar to the SVMNT haplotype, which originated from South America ( [@B21] ). Multi- *locus* microsatellite studies have also illustrated a greater evolutionary affinity between *P. falciparum* isolates from PNG and Southeast Asia, as opposed to South America, which further emphasises the unexpected nature of the *Pfcrt* polymorphism findings ( [@B92] ). However, apart from the *Pfcrt* substitutions, S ~agt~ VMNT and S ~tct~ VMNT have been associated with a different genetic background in PNG and South America, respectively and as such, it has been argued that PNG most likely represents another independent focus of CQR ( [@B21] ). In PNG, apart from the S ~agt~ VMNT haplotype, which occurs at appreciable frequency, two CVIET-derived haplotypes (SVIET and CVIKT) have also been reported with minor frequency in Indonesian Papua (West New Guinea) ( [@B106] , [@B30] , [@B147] ). In the East Timor Islands, Solomon Islands and Vanuatu, the SVMNT haplotype is prevalent ( [@B151] , [@B130] , [@B4] , [@B98] , [@B147] ). In Indonesia, apart from the highly frequent SVMNT haplotype, a new haplotype, CVMNN, was found to be frequent in Lombok and Irian Jaya ( [@B68] ). Most interestingly, India has a mixture of many CQR- *Pfcrt* haplotypes, which are primarily dominated by SVMNT, but also show appreciable frequencies of CVIET, CVMNT and CVIDT ( [@B159] , [@B160] , [@B157] , [@B98] , [@B74] [@B111] , [@B16] , [@B99] , [@B9] , [@B146] , [@B85] ). In Pakistan, Iran and Sri Lanka, the S ~agt~ VMNT haplotype is reported at appreciable frequencies and is believed to have been imported from India ( [@B180] , [@B181] , [@B122] ). A very recent study from Yemen and Saudi Arabia confirmed the major presence of the CVIET haplotype ( [@B2] ).

*Distribution of the CQR-Pfcrt haplotypes in Africa* - The *Pfcrt* CQR haplotypic view in Africa is completely biased towards the CVIET haplotype, owing to the wide usage of CQ and amodiaquine (AQ) drugs in many African countries ( [@B33] ). To date, in most sub-Saharan African countries, including Comoros, Senegal, Gabon, Djibouti, Cameroon, Gambia, Niger, Ivory Coast, Ghana, Nigeria, Kenya, Mali, the Dominican Republic of Congo, Guinea Bissau, Mozambique, Benin, Zambia, Rwanda, Burundi, Tanzania, the Republic of South Africa, Sudan, Congo, Madagascar, Malawi and Uganda, the CVIET haplotype is the only CQR- *Pfcrt* haplotype that has been reported in high frequency ( [@B27] , [@B8] , [@B120] , [@B137] , [@B72] , [@B109] , [@B92] , [@B108] , [@B18] , [@B51] , [@B147] ). However, in Tanzania, the SVMNT haplotype is present at an appreciable frequency ( [@B3] ). In Congo and Madagascar, two CVIET-derived haplotypes are also present, SVIET in Congo and CVIDT in Madagascar ( [@B137] , [@B121] ). Interestingly, the Central African Republic shows the CVIET haplotype at an appreciable frequency, along with six derived haplotypes (SVIET, SVIEK, CVIEK, CVMNT, SVMET and CVINT) in low frequencies ( [@B93] ). Interestingly, a recent study reported the presence of the S ~tct~ VMNT haplotype in a very high frequency in Angola, with a low frequency of CVIET and three derived haplotypes (CVMNT, CVINT and CVMDT) with relatively lower frequencies ( [@B53] ). Furthermore, high CQR- *Pfcrt* haplotype diversity and the emergence of the S ~agt~ VMNT haplotype in Cameroon have recently been reported ( [@B90] ). Thus, in general, while all of the African countries were found to be dominated by the CVIET *Pfcrt* -CQR haplotype, Angola, Tanzania, Cameroon and the Central Africa Republic were exceptions. It seems probable that the SVMNT haplotype found in Angola, Tanzania, Cameroon and the Central African Republic might have originated in South America and the Western Pacific. Because Angola and Cameroon are located on the Southwest coast of Africa, these countries might have received the CQR *Pfcrt* migrants of *P. falciparum* from South America due to frequent travellers between Brazil and Africa ( [@B53] , [@B44] ) and due to an increase in the use of AQ in Africa either alone or in combination with artesunate ( [@B145] ). Regardless, the presence of seven different haplotypes (CVIET, SVIET, SVIEK, CVIEK, CVMNT, SVMET and CVINT) in the Central African Republic might be explained with a better knowledge of the drug combinations administered in this region to date ( [@B93] ), as the increasing use of AQ in Africa poses the threat of a selective sweep of highly AQ and CQ-resistant parasites with *Pfcrt* and *Pfmdr1* mutations that are as advantaged and persistent as in South America ( [@B129] ).

*Distribution of the CQR-Pfcrt haplotypes in South America* - South America is thought to be one of the six foci of origin of CQR *P. falciparum* , as the CQR- *Pfcrt* haplotype S ~tct~ VMNT was first reported at the Colombia-Venezuela border ( [@B91] , [@B92] ) and is still highly prevalent across the continent. The high prevalence of the S ~tct~ VMNT haplotype in South American countries is attributed to many factors, such as (i) the absence of CQ pressure, (ii) the wide usage of AQ, (iii) region-specific differences in drug usage, (iv) a reduced rate of polyclonal infections and (v) the absence of competitive wild type parasites ( [@B129] , [@B128] , [@B44] ). The highly prevalent S ~tct~ VMNT haplotype is reported to be the sole haplotype in Bolivia. In Brazil, Venezuela and Peru, the S ~tct~ VMNT haplotype is present in high frequency, along with the CVIET haplotype, at an appreciable frequency ( [@B128] ). In contrast, Ecuador and Guyana are completely dominated by the SVMNT-derived haplotype CVMNT, with some incidences of S ~tct~ VMNT ( [@B57] ). In Colombia, the S ~tct~ VMNT haplotype was reported initially, but has been replaced by the CVMNT haplotype ( [@B124] ). Apart from these frequent CQR *Pfcrt* haplotypes, three other low-frequency haplotypes, SVMIT and RVMIT in Guyana (Plummer et al. 2004) and CVMET across the Amazon Basin, have also been reported ( [@B28] , [@B158] , [@B43] , [@B115] ). In general, the haplotypic view in South America suggests that the S ~tct~ VMNT haplotype and its derivatives are predominant, with the CVIET haplotype also being present in Brazil and Venezuela ( [@B84] ). The CVIET haplotype has only been rarely reported in South America and was most likely imported from Africa, as most of the parasites in Brazil have the typical SVMNT allele. In Haiti, most of the parasites have the CVMNK allele and CVIET is rare. In this context, it is important to recognise that in Central American countries, including Haiti, CQ remains as the primary drug for the treatment of *P. falciparum* malaria ( [@B84] ). In response to the rise in anti-malarial drug resistance in the Amazon and in South American countries, a surveillance network named Amazon Network for the Surveillance of Antimalarial Drug Resistance was created, with the primary responsibilities of formulating drug policies, monitoring drug resistance and promoting the suitable use of drugs within the continent ( [@B52] ).

*Pfcrt haplotypes and the origin and spread of CQR: any correlation?* - The putative origin and spread of CQR *P. falciparum* was mainly inferred by epidemiological surveillance data ( [@B170] , [@B169] , [@B5] ). Thus, the current distribution patterns of CQR *P. falciparum* are primarily based on this inference and are dependent on the time of the report of CQR *P. falciparum* in any endemic country. Accordingly, three different models based on CQR prevalence data in three separate malaria-endemic zones, Southeast Asia, Africa and South America ( [@B10] ), have been suggested. According to the first model, CQR *P. falciparum* possibly originated independently in Southeast Asia (Thailand-Cambodia border) and South America (Venezuela-Colombia border) during 1957 and 1959, respectively. By 1980, CQR *P. falciparum* populated a maximum number of Asian countries ( [Table I](#t01){ref-type="table"} ). Similarly, in South America, Peru and Bolivia reported incidences of CQR *P. falciparum* in 1980 ( [Table I](#t01){ref-type="table"} ). In Africa, CQR *P. falciparum* was reported relatively late. The first report came from Kenya in 1978 and by the early 1990s, CQR *P. falciparum* isolates were found in almost all African countries. Thus, by the end of the 1980s and in the early 1990s, almost all of the malaria-endemic countries worldwide had some form of CQR *P. falciparum* .

Since the discovery of the distinct genetic lineages of Southeast Asian (CVIET), South American (S ~tct~ VMNT) and Southeast Asian and Asian (S ~agt~ VMNT) *Pfcrt* , the epidemiological observations of rare origin and contiguous spread have been interpreted as evidence of a rare and complex underlying genetic mechanism of CQR ( [@B116] , [@B10] ). Some early studies on the molecular epidemiology of CQR suggested that resistant malaria arose both focally and locally in direct response to CQ drug pressure ( [@B170] , [@B169] ). Moreover, it has been suggested that CQR *Pfcrt* haplotypes resulting from amino acid changes at positions 72-76 are strongly associated with the geographic region-restricted evolution of *P. falciparum* resistance to CQ and that these haplotypes are good estimators for predicting evolution and geographical spread of resistance, as other polymorphisms outside these positions have no clear geographical association with CQR ( [@B97] , [@B96] ).

The differential distribution of the most frequently found CQR *Pfcrt* haplotypes offers opportunities to track the movement of these haplotypes, creating a haplotypic view across continents and to indirectly infer the spread of CQR *P. falciparum* . Recently conducted studies in both worldwide and Indian populations have clearly revealed that such patterns can be inferred from several CQR *Pfcrt* haplotypes, thus offering the opportunity to correlate these patterns with the epidemiological surveillance data on CQR *P. falciparum* parasites ( [@B9] , [@B10] ). Accordingly, the CVIET haplotype populated all of Southeast Asia by the early 1970s and reached India by 1973. This haplotype moved out of Asia and into Africa and this fact is well correlated with the epidemiological data ( [@B9] , [@B10] ). Alternatively, the CVIET haplotype might have moved from the Southeast Asian countries across the Pacific to South America, which is reflected by the presence of the CVIET haplotype in Venezuela and Brazil, although it is only present in a small percentage ( [@B25] , [@B28] , [@B57] ). Alternatively, the presence of the CVIET haplotype in Brazil and Venezuela ( [@B158] ) may be due to its movement from geographically close African countries ( [@B9] , [@B10] ). Very similarly, the S ~tct~ VMNT haplotype originated in South America, while the S ~agt~ VMNT haplotype originated in PNG ( [@B92] ). These haplotypes first spread locally within the respective continents before migrating to other malaria-endemic regions. As a result, the S ~tct~ VMNT haplotype moved eastward to reach West African countries, evidenced by the fact that the S ~tct~ VMNT haplotype is found at an appreciable frequency in Angola and in low frequency in Tanzania ( [@B3] , [@B53] ). Within Asia, the S ~agt~ VMNT haplotype, which originated in PNG, established itself quite successfully in many places, over-dominating the original haplotype, CVIET, especially in India, Pakistan, Sri Lanka, PNG, the Philippines and Iran. It seems that Iran received this haplotype (and CVIET) from India and Pakistan ( [@B9] , [@B10] , [@B122] ). Additionally, the CVIET haplotype could have spread to Yemen and Saudi Arabia from either Iran or Africa ( [@B2] ). However, the global spread of CQR *P. falciparum* , as inferred from the epidemiological surveillance data, does not completely correlate with the inferred movements of the CQR *Pfcrt* haplotypes ( [@B10] ). In turn, the routes inferred by the CQR *Pfcrt* haplotype data correlate well with the intercontinental usage of anti-malarials and the migration and successful establishment of CQR *P. falciparum* in different parts of the world ( [@B10] ). For example, in places such as South America, AQ and CQ, which were not in use for the past several years, have resulted in the complete fixation of the S ~tct~ VMNT haplotype ( [@B129] ). On the contrary, dramatic changes have been observed after discontinued drug pressure in certain African countries and Southeast Asia. In the absence of drug pressure, the SVMNT haplotype provides equal fitness to *P. falciparum* (as in the presence of drug pressure) in comparison to the CVIET haplotype ( [@B129] ). Furthermore, CVIET haplotype-bearing *P. falciparum* are known to revert back to the CQS (CVMNK) type ( [@B79] , [@B94] , [@B10] ), whereas SVMNT-bearing *P. falciparum* do not ( [@B47] ). For example, a region of Malawi that is known for highly prevalent CQR was re-populated with drug-sensitive parasites within 10 years after CQ use was stopped ( [@B79] ). A similar recovery of CQS *P. falciparum* populations was recently reported in Kenya and has also been observed in China ( [@B164] , [@B105] ). These changes in the absence of drug pressure have also been explained by fitness costs that are carried by CQ-resistant mutants ( [@B81] ). However, such a selective disadvantage has been less apparent in South America, where CQS parasites have not replaced their CQ-resistant counterparts. A satisfactory explanation for this difference between the Southeast Asian/African and South American forms of CQR has not been proposed ( [@B129] ). This contention also supports the hypothesis that approximately 70% of the total *Pfcrt* -CQR haplotypes in Southeast Asia and South America are S ~agt~ VMNT and S ~tct~ VMNT, respectively ( [@B9] , [@B10] ).

*Evolutionary puzzle of the Pfcrt gene in India* - India is a country where malaria is highly endemic and where CQR *P. falciparum* is widely prevalent ( [@B138] , [@B142] ). CQR *P. falciparum* was first detected as early as 1973 in the Asom state of India ( [@B136] ). Genetic studies of CQR *Pfcrt* revealed the presence of four major haplotypes (CVIET, SVMNT, CVMNT and CVIDT) in India, with the SVMNT haplotype populating the majority of the Indian states compared to the CVIET haplotype ( [@B9] ). In India, the predominant distribution of the SVMNT haplotype, compared to the minimal presence of the CVIET haplotype, is quite puzzling. Because India is geographically closer to Southeast Asia (Thailand, Cambodia, Bangladesh, Laos) than to PNG and Oceania, it is expected that India should share its haplotypic status with Southeast Asia (high frequency of the CVIET haplotype). However, in reality, India shares its CQR- *Pfcrt* haplotypic status with PNG, Indonesia and Oceania, which harbour the S ~agt~ VMNT haplotype. Furthermore, based on the distribution of the four haplotypes (S ~agt~ VMNT, CVIET, CVMNT and CVIDT), the two following routes of possible migration of *Pfcrt* haplotypes (SVMNT and CVIET) into India have been hypothesised: (i) while the S ~agt~ VMNT haplotype originated in PNG, it travelled through PNG ↔ Indonesia ↔ the Philippines ↔ Malaysia ↔ Andaman and the Nicobar Islands and then entered mainland India through the east coastal state of Odisha and the S ~tct~ VMNT haplotype originated in South America, travelled through South America ↔ PNG ↔ Indonesia ↔ the Philippines ↔ Malaysia ↔ Andaman and the Nicobar Islands and reached India *via* Odisha. Similarly, (ii) the CVIET haplotype from the Thailand-Cambodia border travelled from Thailand and Cambodia through Myanmar to populate Mizoram and other Northeastern Indian states and reached as far as Karnataka (Southern India) ( [@B9] ). A recent microsatellite variation study of the *Pfcrt* gene and its adjacent sequences in the Indian population suggested that the CQR- *Pfcrt* haplotypes might have originated in Southeast Asia and spread into Eastern India and other parts of this country through the Northeastern regions ( [@B87] ). Although these routes were inferred from in-depth population genetic analyses of the currently available data on the CQR *Pfcrt* haplotypes, the complexity of the prevalence and distribution of the S ~agt~ VMNT haplotype has confounded the overall scenario of the distribution of the CQR *Pfcrt* haplotypes in India ( [@B157] ), as India and Iran have also been labelled as the sixth focus of origin of CQR *P. falciparum* parasites ( [@B92] , [@B180] , [@B167] ).

Another interesting and puzzling issue is the evolutionary course of the *Pfcrt* gene in India. It is widely known from global genetic diversity studies of CQR isolates that because the *Pfcrt* gene is responsible for an important function in *P. falciparum* and is targeted by natural selection, it is described under the "selective sweep" model ( [@B23] , [@B177] ). This model perfectly fits the explanation of the origin and subsequent proliferation of CQR malaria parasites across the globe ( [@B177] , [@B103] , [@B161] ). However, genetic diversity data on the *Pfcrt* gene from CQR *P. falciparum* in India do not conform to this evolutionary model ( [@B98] , [@B160] , [@B31] ). Although a very recent study provided evidence on the role of natural selection in the evolution of the *Pfcrt* gene in India ( [@B99] ), the inferences of this study are unclear for the two following reasons: (i) the aims of the study were to correlate cerebral malaria with drug resistance gene polymorphisms and thus, the study contains sample bias and (ii) the study analysed only a single population from central India ( [@B99] ). Considering that India is a vast country with a variable climate and malaria epidemiology ( [@B142] ), the mystery of *Pfcrt* gene evolution needs to be resolved by deep sampling and finer evolutionary analyses.

*Is Pfcrt the sole candidate for CQR?* - To visualise the relevance of the genetic basis of any drug resistance from a public health perspective, an absolute correlation between genotype and phenotype is essential. In this respect, *Pfcrt* has not met all of the requirements for determining this gene as the sole agent of CQR. In fact, several studies have indicated that it is unclear if the *Pfcrt* gene is directly and solely associated with CQR *P. falciparum* . For example, (i) not all of the CQR *P. falciparum* isolates were found to bear the K76T mutation in the *Pfcrt* gene and *vice versa* ( [@B159] ), (ii) the *Pfcrt* homologue in *P. vivax* ( *Pvcrt-o* ) is not associated with CQR in *P. vivax* ( [@B88] ), (iii) the K76T mutation is not sufficient for the transport of CQ via *Pf* CRT, which is consistent with the view that one or more other *Pf* CRT mutations act in concert with K76T to confer CQR ( [@B145] ), (iv) a strong LD was observed in the \~40-Kb region surrounding the *Pfcrt* gene in chromosome 7 ( [@B103] ), supporting the fact that the observed genetic patterns in the *Pfcrt* gene could merely reflect the role of evolutionary force in *hitherto* uncharacterised gene(s) that have a direct association with CQR *P. falciparum* ( [@B58] , [@B103] ) and (v) a strong association was observed between *Pfcrt* and the adjoining *var* gene in the VarS4 region of the *P. falciparum* genome ( [@B50] ). This final observation ( [@B50] ) corroborates the findings of [@B103] , clearly reflecting the importance of the \~100-Kb region of chromosome 7 in the *P. falciparum* genome ( [Fig. 2](#f02){ref-type="fig"} ) rather than the *Pfcrt* gene alone. Furthermore, unlike the global pattern depicting the role of natural selection in the evolution of the *Pfcrt* gene ( [@B177] ), the *Pfcrt* gene in Indian *P. falciparum* does not seem to follow the same pattern, which could be due to a shift in the target of selection ( [@B31] ). In addition, the poor correlation between the CQR epidemiological surveillance data and the CQR *Pfcrt* haplotypes ( [@B10] ) weakens the contention that *Pfcrt* is the sole controller of CQR.

*Conclusion and future prospects* - The current genetic understanding of CQR *P. falciparum* not only has provided several meaningful insights and enhanced the knowledge pertaining directly to malaria research, but also has advanced the academic understanding of how a single gene and a single amino acid mutation can significantly affect gross phenotypic characteristics. Because human infectious diseases are difficult to control, mainly due to the development of drug-resistant pathogens and successful environmental adaptation, the detailed genetic understanding of CQR *P. falciparum* may prove to be a model that can be applied to other infectious disease systems. In this regard, enormous amounts of genetic data on the *Pfcrt* gene in global *P. falciparum* have been generated and several genetic, epidemiological and evolutionary hypotheses have been proposed and tested. Furthermore, association studies between the drug response (IC ~50~ values) and SNPs in different candidate genes have identified several associations between the *Pfcrt* gene and CQR.

However, despite this wealth of knowledge, it is unclear if one can reliably consider *Pfcrt* to be the sole gene that is responsible for CQR in *P. falciparum* . Several studies in global *P. falciparum* have suggested that *Pfcrt* is the primary determinant of CQR. At the same time, enough empirical evidence has disputed this hypothesis ( [@B144] , [@B13] , [@B14] , [@B39] ), supporting the presence of secondary determinants of CQR ( [@B44] ). While the role of the *Pfcrt* gene cannot entirely be negated, with increasing bodies of evidence from several genome wide association studies and quantitative trait *loci* analyses of genetic crosses, it is reasonable to hypothesise a role for other gene(s) in conferring CQR in *P. falciparum* ( [@B177] , [@B73] , [@B162] , [@B103] , [@B44] ). For example, a recently conducted genome scan of global *P. falciparum* isolates reported important genomic information on the genetic basis of antimalarial resistance ( [@B104] ). In particular, a 100-Kb region located in chromosome 7 of the *P. falciparum* genome ( [Fig. 2](#f02){ref-type="fig"} ) was found to have very low recombination activity (Gupta et al. 2010, [@B103] ). This region contains eight transporter genes (CG1, CG2, CG3, CG4, *Pfcrt* , CG6, CG7, CG8) ( [Fig. 2](#f02){ref-type="fig"} ). Furthermore, evidence for the tight linkage between genes located in this chromosomal region has also been documented ( [@B50] ). Taken together, these data support the hypothesis that other gene(s) located within this linked genetic block on chromosome 7 in *P. falciparum* might also play a role in conferring CQR, either alone or in close functional associations with the *Pfcrt* gene. Specifically, one of these eight transporter genes ( [Fig. 2](#f02){ref-type="fig"} ), *CG2* , when placed downstream of the *Pfcrt* , has been shown to be phenotypically associated with CQR (Su et al. 1997, [@B13] , [@B14] , [@B39] ). However, the association between CQR and the *CG2* genotype is not sufficient to completely justify an exclusive role for the *CG2* gene in CQR ( [@B58] ).

Based on the currently available data, it seems that the \~100-Kb region in chromosome 7 in the *P. falciparum* genome holds the key for the determination of CQR ( [@B58] , [@B103] ). Considering the dubious role of *Pfcrt* and the possible involvement of other nearby transporter genes, further evolutionary genetic studies ( [@B143] ) in this 100-Kb region could provide novel insights into the genetic basis of the *P. falciparum* drug resistance mechanisms ( [@B58] ) and identify previously unknown genes that may be involved in determining CQR in *P. falciparum* . Further functional validation of such novel genes could possibly clarify the genetic determinants of CQR *P. falciparum* . This clarification will not only provide new directions for malaria research and further our understanding of the molecular epidemiology of *P. falciparum* malaria, but also contribute to the development of new genetic control measures for malaria. This increased understanding could also improve the management of other human infectious diseases that are dominated by drug-resistant pathogens.
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